logo

Savara Inc (SVRA)



Trade SVRA now with
  Date
  Headline
12/30/2019 8:12:20 AM Principia Biopharma Updates PRN1008 Pemphigus Clinical Program
12/30/2019 8:08:49 AM Savara Granted Breakthrough Therapy Designation For Molgradex For Autoimmune Pulmonary Alveolar Proteinosis Treatment
12/3/2019 4:07:56 PM Savara Appoints An Van Es-Johansson To Board Of Directors
10/2/2019 8:05:01 AM Savara Announces FDA Response From Type C Meeting On Molgradex For APAP Development Program
12/19/2018 8:08:27 AM Savara Announces Interim Results From OPTIMA, A Phase 2a Clinical Study
9/27/2018 8:12:12 AM Savara Provides Enrollment Update On Molgradex Impala And OPTIMA Clinical Studies; Affirms View For Topline Data
9/18/2018 7:00:36 AM BioTime Implements New Leadership Structure; Appoints Brian Culley As CEO
8/9/2018 4:05:17 PM Savara Q2 Loss Per Share Of $0.38 Vs. $0.90 Last Year
7/26/2018 9:17:37 AM Savara Prices Public Offering Of 4.25 Mln Shares At $11.50 Per Share
7/25/2018 4:28:37 PM Savara Announces Proposed Public Offering Of Common Stock
5/29/2018 8:08:18 AM Savara Update On Case Reports Of Inhaled Granulocyte-Macrophage Colony Stimulating Factor For Treatment Of NTM
3/13/2018 8:04:32 AM Savara Initiates Phase 2a Study Of Molgradex For Treatment Of NTM Lung Infection
  
 
>